跳至主要内容
临床试验/IRCT20230618058520N1
IRCT20230618058520N1已完成2 期

Investigating the effect of injectable ketamine with doses of 0.5 mg/kg on the control of symptoms in patients with treatment-resistant major depressive disorder: a randomized clinical trial

Vice Chancellor for Research and Technology, Shahrood Islamic Azad University0 个研究点目标入组 15 人开始时间: 待定最近更新:

试验速览

阶段
2 期
状态
已完成
发起方
入组人数
15

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

年龄范围
no limit 至 no limit(—)
性别
All

入选标准

  • Patients with treatment-resistant major depressive disorder based on DSM IV _ TR criteria
  • Being in a depressive episode
  • Failure to respond to antidepressants and shock medications and failure to control symptoms with other methods
  • Intolerance of oral antidepressants

排除标准

  • More serious psychiatric disorders: bipolar 1 and 2 - cyclothymia - psychosis - obsession - ski and affective
  • Addiction or withdrawal from drugs
  • Personality disorder
  • Physical diseases such as: thyroid disorders, diabetes, hypertension, stroke, brain surgeries, etc.
  • Response to drug treatment and control of disease symptoms with drugs
  • Received ECT two months before starting ketamine treatment
  • Receiving antidepressant medication one month before starting ketamine treatment
  • Lack of consent to participate in the study
  • Cardiovascular problems
  • Pregnancy and breastfeeding

研究者

发起方
Vice Chancellor for Research and Technology, Shahrood Islamic Azad University

相似试验